The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 04, 2014

Filed:

Dec. 14, 2011
Applicants:

Shafiqul I. Chowdhury, Baton Rouge, LA (US);

Hui Yong Wei, Baton Rouge, LA (US);

Inventors:

Shafiqul I. Chowdhury, Baton Rouge, LA (US);

Hui Yong Wei, Baton Rouge, LA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/245 (2006.01); C12N 15/63 (2006.01); C12N 7/01 (2006.01); A61P 31/22 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/245 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/552 (2013.01); C12N 2710/16771 (2013.01); C12N 2710/16734 (2013.01); C12N 7/00 (2013.01); C12N 2710/16762 (2013.01);
Abstract

A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 U49.5Δ30-32 CT-null virus was made and tested. This mutant virus was then used to incorporate additional changes, e.g., the glycoprotein E cytoplasmic-tail deletion, the Us9 deletion, or both. This triple mutant BHV-1 U49.5Δ30-32 CT-null/gE CTΔ/Us9Δ virus will be superior to the current BHV-1 mutants because the mutant virus will not be shed following reactivation, will be a DIVA based on gE CT-specific serum antibodies, and will induce better protective response by inducing higher SN titers and better cellular immune response. This new virus will have sufficient viral replication in the nasal epithelium and will be a good vaccine for protection of cattle from BHV-1. The new mutant viruses can also be used as vectors for exogenous genes.


Find Patent Forward Citations

Loading…